Syncom formulations (India) Limited has filed its annual disclosure under SEBI (SAST) Regulations for the financial year ended March 31, 2026. The WHO-GMP and ISO 9001:2015 certified pharmaceutical company submitted the mandatory yearly disclosure to stock exchanges and its Audit Committee on April 6, 2026.

Regulatory Compliance Filing

The disclosure was filed pursuant to Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Company Secretary and Compliance Officer Vaishali Agrawal submitted the filing to both BSE Limited and National Stock Exchange of India Limited on behalf of the company.

Promoter Declarations

Both promoters of Syncom Formulations have provided individual declarations confirming compliance with SEBI regulations. The declarations were signed on April 3, 2026, from their respective locations.

Kedarmal Shankarlal Bankda Declaration

Kedarmal Shankarlal Bankda, Promoter and Whole-time Director (DIN: 00023050), declared that he and his persons acting in concert have not made any new encumbrances on company securities during FY26. His PAC group includes:

• Smt. Vimla Bankda (Person Acting in Concert)
• Shri Ankit Bankda (Person Acting in Concert)
• Kedarmal Shankarlal Bankda (HUF) (Person Acting in Concert)

Vijay Shankarlal Bankda Declaration

Vijay Shankarlal Bankda, Promoter and Managing Director (DIN: 00023027), submitted a similar declaration covering his extended PAC network of nine entities:

Corporate Information

Syncom Formulations operates from multiple locations with its registered office in Mumbai, corporate office in Indore, and manufacturing facility in Pithampur, Madhya Pradesh. The company maintains its commitment to regulatory compliance through timely submission of required disclosures to market regulators and stakeholders.

Syncom formulations (India) Limited has officially notified BSE and NSE that it does not fall under the category of "Large Corporate" as defined by SEBI regulations. The WHO-GMP and ISO 9001-2000 certified pharmaceutical company submitted this confirmation on April 3, 2026, ensuring compliance with regulatory disclosure requirements.

Regulatory Framework and Compliance

The company's confirmation references multiple SEBI circulars that define Large Corporate criteria. The primary regulation cited is SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, which was subsequently updated on April 13, 2022. Additional regulatory guidance comes from SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, along with BSE Notice No. 20220427-2 dated April 27, 2022.

Exemption from Annual Disclosure Requirements

By confirming its non-Large Corporate status, Syncom Formulations is exempt from submitting the Annual Disclosure in Annexure B2 for the financial year ended March 31, 2026. This exemption reduces the company's regulatory compliance burden while maintaining transparency with investors and stakeholders.

Corporate Communication and Filing

The confirmation was digitally signed by Vaishali Agrawal, Company Secretary and Compliance Officer, on April 3, 2026. The document was filed online through the official portals of both stock exchanges - www.listing.bseindia.com for BSE and the NEAPS portal for NSE. The company has requested both exchanges to disseminate this information on their websites for investor awareness.

Company Profile

Syncom Formulations operates as a WHO-GMP and ISO 9001-2000 certified pharmaceutical company with CIN No. L24239MH1988PLC047759. The company maintains multiple operational locations including its registered office in Mumbai, manufacturing works in Pithampur, Madhya Pradesh, and corporate office in Indore. The company trades on BSE under code 524470 and on NSE under the symbol SYNCOMF.